Home/Pipeline/Rusfertide (PTG-300)

Rusfertide (PTG-300)

Polycythemia Vera

Phase 3VERIFY study completed

Key Facts

Indication

Polycythemia Vera

Phase

Phase 3

Status

VERIFY study completed

Company

Protagonist Therapeutics

About Protagonist Therapeutics

Protagonist Therapeutics leverages its proprietary peptide discovery platform to develop innovative therapies for rare and prevalent diseases where current treatments are inadequate. The company has achieved significant clinical milestones with rusfertide nearing NDA filing for polycythemia vera and icotrokinra advancing through Phase 3 trials for psoriasis and other inflammatory conditions through its partnership with Janssen. With multiple programs spanning hematology, immunology, and metabolic diseases, Protagonist is positioned as a leader in peptide therapeutics with potential for multiple near-term commercial launches.

View full company profile

Therapeutic Areas

Hematology Immunology Inflammation Metabolic Diseases Dermatology Gastroenterology

Other Polycythemia Vera Drugs

Drug	Company	Phase	Status
BESREMi® (Ropeginterferon alfa-2b)	PharmaEssentia	Commercial	Approved
DISC-3405	Disc Medicine	Phase 2	Active (Fast Track Designation)